- Home
- ICU vs POAI Comparison
ICU vs POAI Comparison
Compare ICU & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- POAI
- Stock Information
- Founded
- ICU 2018
- POAI 2002
- Country
- ICU United States
- POAI United States
- Employees
- ICU N/A
- POAI N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- ICU Health Care
- POAI Health Care
- Exchange
- ICU Nasdaq
- POAI Nasdaq
- Market Cap
- ICU 10.4M
- POAI 8.9M
- IPO Year
- ICU N/A
- POAI N/A
- Fundamental
- Price
- ICU $0.46
- POAI $0.85
- Analyst Decision
- ICU
- POAI Hold
- Analyst Count
- ICU 0
- POAI 1
- Target Price
- ICU N/A
- POAI N/A
- AVG Volume (30 Days)
- ICU 16.0M
- POAI 101.5K
- Earning Date
- ICU 08-12-2025
- POAI 08-12-2025
- Dividend Yield
- ICU N/A
- POAI N/A
- EPS Growth
- ICU N/A
- POAI N/A
- EPS
- ICU N/A
- POAI N/A
- Revenue
- ICU $428,000.00
- POAI $1,729,269.00
- Revenue This Year
- ICU $754.07
- POAI $486.27
- Revenue Next Year
- ICU $100.09
- POAI $65.50
- P/E Ratio
- ICU N/A
- POAI N/A
- Revenue Growth
- ICU N/A
- POAI 24.17
- 52 Week Low
- ICU $0.31
- POAI $0.55
- 52 Week High
- ICU $13.85
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- ICU 20.54
- POAI 38.72
- Support Level
- ICU $0.39
- POAI $0.81
- Resistance Level
- ICU $0.45
- POAI $0.91
- Average True Range (ATR)
- ICU 0.12
- POAI 0.06
- MACD
- ICU -0.05
- POAI -0.00
- Stochastic Oscillator
- ICU 12.17
- POAI 16.00
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.